Example: Heart Attack

Search clinical trials for: Trypsin Inhibitors

Total 124 results

NCT03443180

Active, not recruiting

Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet

Conditions: Type1diabetes
NCT02647554

Recruiting

Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

Conditions: Sepsis; Septic Shock
NCT02895191

Unknown status

The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)

Conditions: Acute Respiratory Distress Syndrome
NCT02527811

Unknown status

Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery

Conditions: Congenital Heart Diseases
NCT02520570

Unknown status

Post-market Safety Reassessment of Ulinastatin for Injection

Conditions: Adverse Reaction to Drug
NCT01132521

Suspended

Ulinastatin in Severe Acute Pancreatitis

Conditions: Pancreatitis
NCT03664531

Recruiting

Dietary Triggers of Gastrointestinal Symptoms in IBS Patients

Conditions: Irritable Bowel Syndrome
NCT01523821

Completed

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Conditions: Graft-Versus-Host Disease (GVHD) Acute on Chronic
NCT04547140

Recruiting

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

Conditions: COVID-19
NCT01731691

Terminated

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

Conditions: HIV Disease
NCT04440488

Withdrawn

ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study

Conditions: Chronic Obstructive Pulmonary Disease; Alpha1-antitrypsin Deficiency
NCT04167514

Recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

Conditions: Graft Versus Host Disease (GVHD)
NCT01370018

Completed

Therapy to Elevate CD4 Counts in HIV-1 Disease

Conditions: HIV Disease
NCT04495101

Recruiting

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

Conditions: COVID-19
NCT03805789

Recruiting

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Conditions: Graft Versus Host Disease
NCT02093221

Terminated

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Conditions: Type 1 Diabetes Mellitus
NCT01684410

Completed

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Conditions: Cystic Fibrosis
NCT02525861

Completed

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

Conditions: Alpha1-antitrypsin Deficiency
NCT02722304

Terminated

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Conditions: Chronic Obstructive Pulmonary Disease; Alpha1-antitrypsin Deficiency
NCT01213043

Completed

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Conditions: Emphysema; Alpha 1-antitrypsin Deficiency (AATD)
NCT00670007

Completed

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Conditions: Emphysema; Alpha 1-proteinase Inhibitor Deficiency
NCT00396006

Completed

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Conditions: Alpha 1-Antitrypsin Deficiency
NCT00313144

Terminated

Aralast alpha1-proteinase Inhibitor Surveillance Study

Conditions: Alpha1-antitrypsin Deficiency
NCT00242385

Completed

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Conditions: Alpha 1-Antitrypsin Deficiency
NCT00486837

Completed

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients

Conditions: Cystic Fibrosis